Business
Aclarion to Present 2-year Follow Up Data on Pivotal Clinical Trial Linking Nociscan to Better Surgical Outcomes for Discogenic Low Back Pain
Superior Clinical Outcomes for NociscanTM Proving to be Durable at Two YearsTwo Year Results and the Schedule of Future Clinical Trials to be Outlined at the
About this update from Aclarion, Inc.
[{"type":"text","content":"Superior Clinical Outcomes for NociscanTM Proving to be Durable at Two YearsTwo Year Results and the Schedule of Future Clinical Trials to be Outlined at the Annual State of Spine Surgery Think Tank 2022SAN MATEO, CA / ACCESSWIRE / June 22, 2022 / Aclarion, Inc. (\"Aclarion\" or the \"Company\") (NASDAQ:ACON)(NASDAQ:ACONW), a healthcare technology company that is leveraging biomarkers and proprietary algorithms to identify the location of chronic low back pain, announced today that the Company will be participating in the 17th Annual State of Spine Surgery Think Tank in Los Cabos, Mexico, June 22-25, 2022, where it will be presenting 2-year follow up data on its pivotal clinical trial published in the European Spine Journal in 2019. The company will also outline its schedule for release of an economic analysis report and initiation of future clinical studies aimed at establishing Nociscan as a standard of care for chronic low back pain.Nociscan is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. The technology leverages magnetic resonance spectroscopy (MRS) and proprietary algorithms to identify and analyze chemical biomarkers in the discs demonstrated to be associated with pain. When used with other diagnostic tools, the Aclarion solution provides critical insights into the location of the patient's lower back pain, giving physicians clarity to optimize treatment strategies.On Friday, June 24th, Nociscan will be showcased in a presentation titled, \"Aclarion: Resolving the Discogenic Low Back Pain Dilemma,\" to be presented by Robert Eastlack, MD, Division Head, Spine Surgery, Scripps Clinic Medical Group. \"I was introduced to Aclarion's pioneering innovation several years ago,\" stated Dr. Eastlack. \"Nociscan objectively measures pathological disc pain in a noninvasive manner, which addresses one of the biggest problems in our industry. Aclarion's solution provides me with never-before-available, critical information that helps me better diagnose and treat my chronic low back pain patients.\"In a paper published in the European Spine Journal in 2019, 97% of patients who had surgical intervention for chronic discogenic low back pain met the criteria for significant clinical improvement at one year follow up if all the discs identi...